LIfT BioSciences presents preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at American Society of Gene & Cell Therapy 28th Annual Meeting
showcasing its versatility in diseases beyond oncology London, 22  May 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly...
May 22
LIfT BioSciences presents latest data on its first-in-class Immunomodulatory Alpha Neutrophils at International Society for Cell and Gene Therapy
London, 19 May 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...
May 19
LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland
London , 28 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...
Apr 28
Professor John Campbell PhD FRSB shares insights into how treatment resistance in solid tumours can be overcome
We spoke to Professor John Campbell PhD FRSB, a member of our Scientific Advisory Board, to discuss a key question in oncology: How can treatment resistance in solid tumours be overcome?
Apr 24
Dr. Mark A. Exley shares what excites him most about joining LIfT as Chief Scientific Officer and the potential of LIfT’s technology
In this video, Dr. Mark A. Exley shares his background in biotech, what makes our neutrophil-based approach to cancer therapy so...
Apr 8
